The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia

Po Yu Chen, Mong Liang Lu, Ming Chyi Huang, Chung Feng Kao, Po Hsiu Kuo, Chih Chiang Chiu, Shih Ku Lin, Chun Hsin Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60% and 40%) lost more than 7% of their body weight after metformin treatment as compared with their homozygous counterparts (21.7% and 15.4%, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia.

Original languageEnglish
Pages (from-to)574-578
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume35
Issue number5
DOIs
Publication statusPublished - Oct 12 2015

Fingerprint

Metabolome
Clozapine
Metformin
Schizophrenia
Obesity
Alleles
Placebos
Body Weight
Insulin
Blood Pressure
Therapeutics
Population
Genes

Keywords

  • GNPDA2
  • metformin
  • schizophrenia
  • SH2B1
  • TMEM18

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia. / Chen, Po Yu; Lu, Mong Liang; Huang, Ming Chyi; Kao, Chung Feng; Kuo, Po Hsiu; Chiu, Chih Chiang; Lin, Shih Ku; Chen, Chun Hsin.

In: Journal of Clinical Psychopharmacology, Vol. 35, No. 5, 12.10.2015, p. 574-578.

Research output: Contribution to journalArticle

@article{25e4ddbf093a425bb76a5dfb7c84026c,
title = "The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia",
abstract = "Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60{\%} and 40{\%}) lost more than 7{\%} of their body weight after metformin treatment as compared with their homozygous counterparts (21.7{\%} and 15.4{\%}, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia.",
keywords = "GNPDA2, metformin, schizophrenia, SH2B1, TMEM18",
author = "Chen, {Po Yu} and Lu, {Mong Liang} and Huang, {Ming Chyi} and Kao, {Chung Feng} and Kuo, {Po Hsiu} and Chiu, {Chih Chiang} and Lin, {Shih Ku} and Chen, {Chun Hsin}",
year = "2015",
month = "10",
day = "12",
doi = "10.1097/JCP.0000000000000386",
language = "English",
volume = "35",
pages = "574--578",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia

AU - Chen, Po Yu

AU - Lu, Mong Liang

AU - Huang, Ming Chyi

AU - Kao, Chung Feng

AU - Kuo, Po Hsiu

AU - Chiu, Chih Chiang

AU - Lin, Shih Ku

AU - Chen, Chun Hsin

PY - 2015/10/12

Y1 - 2015/10/12

N2 - Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60% and 40%) lost more than 7% of their body weight after metformin treatment as compared with their homozygous counterparts (21.7% and 15.4%, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia.

AB - Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60% and 40%) lost more than 7% of their body weight after metformin treatment as compared with their homozygous counterparts (21.7% and 15.4%, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia.

KW - GNPDA2

KW - metformin

KW - schizophrenia

KW - SH2B1

KW - TMEM18

UR - http://www.scopus.com/inward/record.url?scp=84941282598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941282598&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000386

DO - 10.1097/JCP.0000000000000386

M3 - Article

VL - 35

SP - 574

EP - 578

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -